Insulet (NASDAQ:PODD) PT Raised to $275.00 at Citigroup

Insulet (NASDAQ:PODD) had its price target lifted by Citigroup from $250.00 to $275.00 in a research report sent to investors on Tuesday, Benzinga reports. They currently have a buy rating on the medical instruments supplier’s stock.

A number of other brokerages also recently weighed in on PODD. Piper Sandler boosted their target price on Insulet from $230.00 to $285.00 and gave the stock an overweight rating in a research note on Tuesday, September 17th. BTIG Research cut their price objective on Insulet from $270.00 to $250.00 and set a buy rating on the stock in a research report on Friday, August 9th. Canaccord Genuity Group upped their price objective on Insulet from $236.00 to $269.00 and gave the company a buy rating in a research note on Wednesday, September 25th. UBS Group lifted their target price on Insulet from $211.00 to $223.00 and gave the stock a neutral rating in a research note on Friday, August 9th. Finally, Barclays increased their price target on shares of Insulet from $200.00 to $220.00 and gave the company an equal weight rating in a research report on Monday, August 12th. Four equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus price target of $234.60.

Insulet Trading Down 0.0 %

NASDAQ PODD opened at $229.94 on Tuesday. The company has a current ratio of 3.60, a quick ratio of 2.71 and a debt-to-equity ratio of 1.36. The firm has a market capitalization of $16.10 billion, a P/E ratio of 69.68, a PEG ratio of 4.34 and a beta of 1.21. The business has a fifty day simple moving average of $209.88 and a 200 day simple moving average of $192.02. Insulet has a 12 month low of $125.82 and a 12 month high of $243.98.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing the consensus estimate of $0.56 by ($0.01). Insulet had a net margin of 21.11% and a return on equity of 30.73%. The firm had revenue of $488.50 million during the quarter, compared to analysts’ expectations of $488.00 million. During the same quarter in the prior year, the company earned $0.38 EPS. The business’s revenue for the quarter was up 23.2% on a year-over-year basis. On average, analysts predict that Insulet will post 3.04 EPS for the current fiscal year.

Institutional Investors Weigh In On Insulet

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Capital Research Global Investors increased its position in shares of Insulet by 19.7% during the fourth quarter. Capital Research Global Investors now owns 9,476,623 shares of the medical instruments supplier’s stock valued at $2,056,255,000 after buying an additional 1,556,455 shares during the period. Vanguard Group Inc. increased its holdings in Insulet by 2.1% during the 1st quarter. Vanguard Group Inc. now owns 8,199,114 shares of the medical instruments supplier’s stock worth $1,405,328,000 after acquiring an additional 169,506 shares during the period. Baillie Gifford & Co. lifted its stake in Insulet by 30.8% in the 2nd quarter. Baillie Gifford & Co. now owns 1,886,062 shares of the medical instruments supplier’s stock worth $380,607,000 after purchasing an additional 443,783 shares in the last quarter. Clearbridge Investments LLC boosted its holdings in Insulet by 6.0% in the 2nd quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical instruments supplier’s stock valued at $270,364,000 after purchasing an additional 75,526 shares during the period. Finally, William Blair Investment Management LLC grew its position in shares of Insulet by 3.7% during the 1st quarter. William Blair Investment Management LLC now owns 952,268 shares of the medical instruments supplier’s stock valued at $163,219,000 after purchasing an additional 33,579 shares in the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.